OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press3310.17650/1818-8346-2013-8-2-41-46HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯThrombotic complications in children with non-Hodgkin lymphomaТромботические осложнения у детей с неходжкинскими лимфомамиLipayN. V.ЛипайН. В.
Russian Federation
nata_lipay@mail.ruFedorovaA. S.ФёдороваА. С.
Russian Federation
DmitrievV. V.ДмитриевВ. В.
Russian Federation
Republican Research Center for Pediatric Oncology, Hematology and ImmunologyГУ «Республиканский научно-практический центр детской онкологии, гематологии и иммунологии»2205201382414621072014210720142013https://oncohematology.abvpress.ru/ongm/article/view/33

Our study was aimed at identifying of risk factors of venous thrombosis (VT) in children with non-Hodgkin lymphomas. VT episodes were registered in 13 of 174 children treated (7.5 %). Possible impact of morphological type, initial mediastinal involvement, gender, age and use of L-asparaginase as a risk factor of thrombosis development were analyzed. Using multivariate analysis primary mediastinal tumor (OR = 4.73 [CI: 1.42–17.10]) and patient age older than 13 years (OR = 4.3 [CI: 1.19–20.28) were identified as prognostic factors of thrombosis development (р < 0,05).

Целью работы явилось выявление факторов риска развития венозного тромбоза (ВТ) у детей с неходжкинскими лимфомами (НХЛ). Эпизоды ВТ были выявлены у 13 из 174 пролеченных детей, т. е. частота ВТ составила 7,5 %. В работе проанализировано возможное влияние таких признаков, как морфологический вариант заболевания, инициальное поражение средостения, пол, возраст, применение L-аспарагиназы в лечебных протоколах, в качестве факторов, предрасполагающих к развитию тромбоза.

Результатами многофакторного анализа подтверждена роль первичной медиастинальной локализации опухоли (OR = 4,73 (CI: 1,42–17,10)) и возраста пациента старше 13 лет в качестве независимых прогностических факторов риска развития тромбоза у детей с НХЛ (OR = 4,3 (CI: 1,19–20,28)), р < 0,05.

venous thrombosischildrennon-Hodgkin lymphomaвенозный тромбоздетинеходжкинская лимфома1. Lee A., Levine M. Venous thromboembolism and cancer: risk and outcomes. Circulation 2003;107:17–21.Lee A., Levine M. Venous thromboembolism and cancer: risk and outcomes. Circulation 2003;107:17–21.2. Lip G.Y., Chin B.S., Blann A.D. Cancer and prothrombotic state. Lancet Oncol 2002;3(1):27–34.Lip G.Y., Chin B.S., Blann A.D. Cancer and prothrombotic state. Lancet Oncol 2002;3(1):27–34.3. Athale U.H., Chan A. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111:199–212.Athale U.H., Chan A. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111:199–212.4. Garth B., Lloyd D. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol 2004;77:331–5.Garth B., Lloyd D. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol 2004;77:331–5.5. Zakarija A., Kwaan H.C. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007;33:355–64.Zakarija A., Kwaan H.C. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007;33:355–64.6. Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5(3):632–4.Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5(3):632–4.7. Kwaan H.C., Vicuna B. Incidence and pathogenesis of thrombosis in hematologic malignances. Semin Thromb Hemost 2007;33(4):303–12.Kwaan H.C., Vicuna B. Incidence and pathogenesis of thrombosis in hematologic malignances. Semin Thromb Hemost 2007;33(4):303–12.8. Caruso V., Di Castelnuovo A., Meschengieser S. et al. Thrombotic complications in patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.Blood 2010;115:5322–8.Caruso V., Di Castelnuovo A., Meschengieser S. et al. Thrombotic complications in patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.Blood 2010;115:5322–8.9. Athale U.H., Chan A.K. Thromboembolic complications in pediatric patients with hematologic malignancies. Semin Thromb Hemost 2007;33(4):416–26.Athale U.H., Chan A.K. Thromboembolic complications in pediatric patients with hematologic malignancies. Semin Thromb Hemost 2007;33(4):416–26.10. Athale U.H., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7.Athale U.H., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7.11. Mitchell L.G. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-Asparaginase. Cancer 2003;97(2):508–16.Mitchell L.G. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-Asparaginase. Cancer 2003;97(2):508–16.12. Mitchell L.G., Lambers M., Flege S. et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of aMitchell L.G., Lambers M., Flege S. et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of amulticentral cohort study. Blood 2010;115(24):4999–5004.13. Swerdlow S.H., Campo E., Harris N.L. et al. WHO Classification of Tumours, Volume 2; IARC WHO Classification of Tumours, No 2. Lyon,France, IARC Press, 2008. 439 p.Swerdlow S.H., Campo E., Harris N.L. et al. WHO Classification of Tumours, Volume 2; IARC WHO Classification of Tumours, No 2. Lyon,France, IARC Press, 2008. 439 p.14. Murphy S.B. Classification, staging and end results of treatment of childhood non- Hodgkins lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1990;7:332–8.Murphy S.B. Classification, staging and end results of treatment of childhood non- Hodgkins lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1990;7:332–8.15. Cazals-Hatem D., Lepage E., Brice P. et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomas de l'Adulte”) study. Am J Surg Pathol 1996;20(7):877–88.Cazals-Hatem D., Lepage E., Brice P. et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomas de l'Adulte”) study. Am J Surg Pathol 1996;20(7):877–88.16. Lipay N.V., Dmitriev V.V., Borisenok M.B. Thrombotic complications during cancer treatment in children. Exp Oncol 2007;29(3):31–5.Lipay N.V., Dmitriev V.V., Borisenok M.B. Thrombotic complications during cancer treatment in children. Exp Oncol 2007;29(3):31–5.17. Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484–90.Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484–90.18. Athale U.H., Nagel K., Khan A.A., Chan A.K.C. Thromboembolism in children with lymphoma. Thromb Res 2008;122:459–65.Athale U.H., Nagel K., Khan A.A., Chan A.K.C. Thromboembolism in children with lymphoma. Thromb Res 2008;122:459–65.19. Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6): 715–22.Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6): 715–22.20. Pusterla S., Previtali S., Marziali S. et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5(4):341–6.Pusterla S., Previtali S., Marziali S. et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5(4):341–6.